Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
06/2003
06/05/2003WO2003046011A1 Antigen presenting cell targeting conjugate an antigen presenting cell contacted with such conjugate their use for vaccination or as medicament and methods for their production or generation
06/05/2003WO2003045973A2 Peptides with growth inhibitory action
06/05/2003WO2003045965A2 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
06/05/2003WO2003045844A1 Calcium metasilicates and methods for making the same
06/05/2003WO2003045438A1 Increasing electro-gene transfer of nucleic acid molecules into host tissue
06/05/2003WO2003045437A1 Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
06/05/2003WO2003045436A1 Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
06/05/2003WO2003045435A1 Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
06/05/2003WO2003045431A2 Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist
06/05/2003WO2003045429A2 Anti-t cell immunotoxin fusion protein and its therapeutic use
06/05/2003WO2003045426A1 T-cell epitodes in carboxypeptidase g2
06/05/2003WO2003045420A2 Use of t-cell immune response cdna 7 (tirc7) for modulation of angiogenesis and/or neovascularization
06/05/2003WO2003045419A1 Injection solution comprising an lhrh antagonist
06/05/2003WO2003045418A1 Medicinal compositions for nasal absorption
06/05/2003WO2003045415A2 Self-assembling p53 peptides as gene delivery vehicles
06/05/2003WO2003045411A2 Ginger extract preparation
06/05/2003WO2003045391A1 Pharmaceutical formulations comprising an immune response modifier
06/05/2003WO2003045371A1 Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
06/05/2003WO2003045366A1 Treatment of wounds and compositions employed
06/05/2003WO2003045357A1 Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
06/05/2003WO2003045356A1 Pharmaceutical dosage form with multiple coatings
06/05/2003WO2003045355A1 Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus
06/05/2003WO2003045354A1 Micropherules containing a pleuromutilin derivative
06/05/2003WO2003045351A1 Controlled release polymeric compositions of bone growth promoting compounds
06/05/2003WO2003045350A2 Device for incorporating substances which contain a sea sponge as a support
06/05/2003WO2003045331A2 Formulations for oral administration of cromolyn sodium
06/05/2003WO2003045326A2 Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
06/05/2003WO2003045319A2 Targeted therapeutics and uses thereof
06/05/2003WO2003045308A2 Formulations for use in medical or diagnostic procedures
06/05/2003WO2003045307A2 Pharmaceutical formulations comprising indolinone derivatives
06/05/2003WO2003045306A2 Phenoxy amine compounds and compositions for delivering active agents
06/05/2003WO2003045305A2 Acetaminophen compositions
06/05/2003WO2003045166A1 Capsule with fast content solubilization and release
06/05/2003WO2003045160A1 Process for preparing chewing gum containing a nutritional supplement
06/05/2003WO2003035043A3 Pharmaceutical formulation comprising more than 15% tamoxifen
06/05/2003WO2003029418A3 Proliferation and differentiation of stem cells using extracellular matrix and other molecules
06/05/2003WO2003020241A9 Functional powders for oral delivery
06/05/2003WO2003011266A3 Azalide antibiotic compositions
06/05/2003WO2003005951A3 Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
06/05/2003WO2002074275A3 Systems for delivering a cosmetic and/or therapeutic active to oral surfaces
06/05/2003WO2002060864A9 Process of obtaining compositions of stable lutein and lutein derivatives
06/05/2003WO2002051446A3 Transfection complexes (transoplex) having a reduced toxicity
06/05/2003WO2002040510A3 Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
06/05/2003US20030105277 Tat transport proteins; antiproliferative agents; antitumor agents
06/05/2003US20030105275 Water-soluble and non-peptidic polymer with a backbone covalently bonded to an alkanoic acid; drug delivery
06/05/2003US20030105245 Combining a star co-polymer with a bis-lactone crosslinking agent, and heating the combined star co-polymer and crosslinking agent, so that a crosslinked biodegradable/biocompatible elastomeric polymer is obtained
06/05/2003US20030105224 Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
06/05/2003US20030105168 Composition comprising ubiquinone
06/05/2003US20030105165 Gap junctions and EDHF
06/05/2003US20030105157 Aqueous solution of ascorbic acid and method for producing same
06/05/2003US20030105156 Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
06/05/2003US20030105144 Celecoxib dissolving in polyethylene glycol; antiinflammatory agents, osteoporosis, respiratory system disorders, antitumor agents, analgesics
06/05/2003US20030105141 Mixture containing fatty acid and aromatic amine; administering by mouth; cyclooxygenase enzyme inhibitor
06/05/2003US20030105051 Nucleic acid treatment of diseases or conditions related to levels of HER2
06/05/2003US20030105031 Administering therapeutically effective amount of one or more flavonoids and carrier for therapy of reactive and inflammatory dermatoses
06/05/2003US20030105027 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
06/05/2003US20030105007 PDGF-betabeta and fibronectin combined in a solid wound dressing for the treatment of wounds
06/05/2003US20030104996 L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
06/05/2003US20030104992 A cyclic polypeptides; immunosuppressive anti-inflammatory activity, inhibiting antigen-induced inflammatory cell infiltration
06/05/2003US20030104990 A cyclosporin mixture comprising a carrier select from 1,2-propylene glycol, glycerides and a surfactant; glycerol-transesterified corn oil, drug bioavailability
06/05/2003US20030104989 A co-polylactames comprising saccharide-modified glutamic acid; drug delivery
06/05/2003US20030104983 A continuous infusion solution, consisting of buffer selected from the group TRIS and arginine, a zinc compound and a phenolic preservatives; treating diabetes, hyperglycemia
06/05/2003US20030104623 Transduction of conjugate polypeptides into tissues
06/05/2003US20030104622 Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
06/05/2003US20030104620 Expression vector for expression of heterologous polypeptides and amplification of cell viral resistance; viricides
06/05/2003US20030104601 Chondroitin synthase gene and methods of making and using same
06/05/2003US20030104591 Methods and compositions for grafting functional loops into a protein
06/05/2003US20030104535 Adheson variants
06/05/2003US20030104377 Tenascin-C nucleic acid ligands
06/05/2003US20030104076 Process for preparing dry extracts
06/05/2003US20030104075 Products containing polyphenol (s) and L-arginine to stimulate nitric oxide production
06/05/2003US20030104072 Optimised pellet formulations
06/05/2003US20030104065 Method of preparing solid dispersions
06/05/2003US20030104063 Low-solubility drug and a matrix combined with a concentration- enhancing polymer. improves stability and/ or enhances concentration
06/05/2003US20030104062 Shell-and-core dosage form approaching zero-order drug release
06/05/2003US20030104061 Controlled release tramadol preparations with a storage-stable release profile and process for their production
06/05/2003US20030104060 Fenofibrate pharmaceutical composition having high bioavailability
06/05/2003US20030104056 Delayed release anti-viral product, use and formulation thereof
06/05/2003US20030104053 Drug dispersed in a solid unitary matrix formed of poly(ethylene oxide) and hydroxypropyl methylcellulose.
06/05/2003US20030104051 Fenofibrate pharmaceutical composition having high bioavailability
06/05/2003US20030104050 Process for preparing quick dissolving, high loading ribavirin compositions
06/05/2003US20030104046 High-concentration lidocaine compositions and methods for their preparation
06/05/2003US20030104045 Novel therapeutic binding molecule complexes
06/05/2003US20030104041 Transdermal and topical administration of drugs using basic permeation enhancers
06/05/2003US20030104040 Balancing the molecular properties (van der Waals forces and dipole moments) of all the components against those of all the components plus the particular active agent.
06/05/2003US20030104031 Controlled release polymeric compositions of bone growth promoting compounds
06/05/2003US20030104020 Chitosan compositions
06/05/2003US20030104015 Emulsion or micellar solution of alpha-tocopherol, one or more surfactants (e.g., a vitamin E derivative), an aqueous phase, and a therapeutic agent
06/05/2003US20030104010 Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
06/05/2003US20030103997 Can be used to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection
06/05/2003US20030103995 Detection and therapy of vulnerable plaque with photodynamic compounds
06/05/2003US20030103990 Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule
06/05/2003US20030103987 Contacting cells of patient with protein having toxic activity of Clostridium sordellii toxin LT under conditions favoring inactivating of Ras by glucosylation of Ras'threonine 35 in cells
06/05/2003US20030103985 Cytotoxic CD44 antibody immunoconjugates
06/05/2003US20030103982 Therapeutic using a bispecific antibody
06/05/2003US20030103963 Complementary determining regions capable binding to the same antigen as the monoclonal antibody 8H9; inhibit competitive binding; isolated scFv of monoclonal antibody 8H9, antigen, antitumor agents
06/05/2003US20030103957 Comprises adenosine-diphosphate transferase activity; drug delivery; for suppressing inhibition of neuronal axon growth
06/05/2003US20030103955 For topical application; high penetration through skin; antiinflammatory agents
06/05/2003US20030103954 Comprises vitamin D3 for regulating cell differentiation and/or cell proliferation
06/05/2003US20030103953 Comprises vitamin D3 for controlling cell differentiation and/or cell proliferation
1 ... 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 ... 1712